Developmental therapeutics
Invited discussant abstracts 359O and 360O_PR
Date
08 Oct 2016Session
Developmental therapeuticsPresenters
Christian RolfoAuthors
C.D. RolfoAuthor affiliations
- Oncology Unit, U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3058 - A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors
Presenter: Shanu Modi
Session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
3319 - 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation in a dose-dependent manner and role of IL-2 receptor-binding
Presenter: Catharina Menke-van der Houven van Oordt
Session: Developmental therapeutics
Resources:
Abstract
Invited discussant abstracts 357O and 358O
Presenter: Christophe Massard
Session: Developmental therapeutics
Resources:
Slides
Webcast
1623 - First-in-human study of AC0010, a novel irreversible, mutant-selective EGFR inhibitor in patients with 1st generation EGFR TKI-resistant non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Developmental therapeutics
Resources:
Abstract
3198 - Phase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels
Presenter: Markus Joerger
Session: Developmental therapeutics
Resources:
Abstract
3573 - Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors
Presenter: Mark Middleton
Session: Developmental therapeutics
Resources:
Abstract
3758 - TAX-TORC: An investigator initiated phase I study combining the dual mTORC1/2 inhibitor AZD2014 in combination with weekly paclitaxel in high-grade serous ovarian cancer
Presenter: Udai Banerji
Session: Developmental therapeutics
Resources:
Abstract
3018 - Molecular imaging of PgP/BCRP inhibition at the blood brain barrier using elacridar and [11C]erlotinib PET
Presenter: Remy Verheijen
Session: Developmental therapeutics
Resources:
Abstract
Invited discussant abstracts 361PD, 362PD and 363PD
Presenter: Irene Braña
Session: Developmental therapeutics
Resources:
Slides
Webcast
4011 - Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
Presenter: Aung Naing
Session: Developmental therapeutics
Resources:
Abstract